Treplacement therapy

Dihydrotestosterone (DHT) (referred to as androstanolone or stanolone when used medically) can also be used in place of testosterone as an androgen. The availability of DHT is limited; it is not available in the United States or Canada, for instance, but it is available in certain European countries, including the United Kingdom , France , Spain , Belgium , Italy , and Luxembourg . [5] DHT is available in formulations including topical gel, buccal or sublingual tablets, and as esters in oil for intramuscular injection. [6] Relative to testosterone, and similarly to many synthetic AAS, DHT has the potential advantages of not being locally potentiated in so-called androgenic tissues that express 5α-reductase (as DHT is already 5α-reduced) and of not being aromatized into an estrogen (it is not a substrate for aromatase).

We included 296 RRT-treated critically ill patients. Of 283 patients with complete data on fluid balance, 76 (%) patients had fluid overload. The median (interquartile range) time from ICU admission to RRT initiation was 14 ( to ) hours. The 90-day mortality rate of the whole cohort was 116 of 296 (%; 95% confidence interval to %). The crude 90-day mortality of patients with or without fluid overload was 45 of 76 (%) vs. 65 of 207 (%), P < . In logistic regression, fluid overload was associated with an increased risk for 90-day mortality (odds ratio ) after adjusting for disease severity, time of RRT initiation, initial RRT modality, and sepsis. Of the 168 survivors with data on RRT use at 90 days, 34 (%, 95% CI to %) were still dependent on RRT.

Treplacement therapy

t replacement therapy


t replacement therapyt replacement therapyt replacement therapyt replacement therapyt replacement therapy